332348-12-6

Basic information

• Product Name: Unii-7D0yb67S97
• Synonyms: 1-25-Oncostatin m (human precursor) fusion protein with ctla-4 (antigen) (human) fusion protein with immunoglobulin G1 (human heavy chain fragment), bimol (146-146')-disulfide;Abatacept;Bms 188667;Bms-188667;Ctla4-ig;Orencia;Unii-7D0yb67S97
• CAS NO: 332348-12-6
• Mol File: 332348-12-6.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Unii-7D0yb67S97(CAS DataBase Reference)
• NIST Chemistry Reference: Unii-7D0yb67S97(332348-12-6)
• EPA Substance Registry System: Unii-7D0yb67S97(332348-12-6)

Safety Data

• Hazardous Substances Data: 332348-12-6(Hazardous Substances Data)

Usage

Description

Unii-7D0yb67S97, also known as Abatacept, is a recombinant protein that serves as a selective co-stimulation modulator. It is a fusion between the extracellular domain of human cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and the modified heavy chain constant segment of human immunoglobulin G1. Abatacept acts as a costimulatory modulator of the CD80/86:CD28 pathway, which plays a central role in the pathogenesis of rheumatoid arthritis (RA).

Uses

Used in Pharmaceutical Industry:
Abatacept is used as a treatment for autoimmune diseases such as rheumatoid arthritis. It functions as a selective co-stimulation modulator, binding to the B7 family of molecules expressed on antigen-presenting cells (APC). By binding to CD80/86 with higher affinity than CD28, Abatacept downregulates T cell costimulation, thereby mimicking endogenous CTLA-4 in its inhibition of T cell costimulation. This helps in reducing inflammation and joint destruction associated with RA.
The immunoglobulin portion of the fusion protein serves as a handle to facilitate purification of the protein, which is produced by recombinant DNA technology in a mammalian cell expression system. It also enhances the solubility and serum half-life of the fusion protein, making it a promising therapeutic candidate for the treatment of RA.

Originator

Bristol–Myers Squibb (US)

Biological Functions

Abatacept, therefore, acts like an antibody that binds with great affinity to B7 ligands, preventing these ligands from interacting with CD28 on activated Tcells. In patients with rheumatoid arthritis, blocking this response by abatacept prevents the generation of positive costimulation signals and stimulation of T-cell activation, suppressing the proliferation of reactive T-cells and the release of more cytokines that destroy tissue, causing the symptoms and signs of arthritis. The extracellular CTLA-4 portion of abatacept is responsible for the affinity of B7. Thus, abatacept slows the damage to bones and cartilage and relieves the symptoms and signs of arthritis.

Clinical Use

Abatacept, the first in a new class of immunosuppressant agents, known as costimulation modulators, acts by down-regulating T-cell activation for the treatment of rheumatoid arthritis. Abatacept is a novel chimeric CTLA-4–IgG1 fused protein created from the fusion of the extracellular domain of the mouse CT LA-4 with the modified heavy-chain constant region of human IgG1.

Side effects

Side effects may include headache, nausea, and mild infections, such as upper respiratory tract infections.

Drug interactions

Potentially hazardous interactions with other drugs Avoid with certolizumab, etanercept, golimumab and infliximab. Vaccines: avoid concomitant use with live vaccines.

Metabolism

Abatacept is cleared via Fc-mediated phagocytosis.